Vraylar (cariprazine) is dosed between 1.5 and 6 mg per day for most approved uses, but the right dose depends heavily on what it is treating. For schizophrenia, the full 1.5–6 mg range applies. For bipolar depression, most of the evidence favors staying at the low end, around 1.5 mg per day. For manic or mixed episodes in bipolar I disorder, doses can go as high as 6 mg per day and, in some clinical trials, up to 12 mg. What makes Vraylar’s dosing unusual compared to many other medications is its exceptionally long-acting metabolite, which stays in your system for weeks after your last pill and influences everything from how quickly the drug kicks in to how long side effects linger.
Starting Dose and the 1.5 mg Increment Rule
Regardless of the condition being treated, Vraylar is started at the lowest available dose: 1.5 mg once daily. From there, increases happen in 1.5 mg steps, meaning your prescriber moves through 1.5, 3, 4.5, and 6 mg per day as needed.1PubMed Central. Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia This slow upward approach is partly because cariprazine and its metabolites accumulate gradually in the body. Bumping the dose too fast can lead to side effects that take weeks to clear, since the drug’s active components stick around far longer than with most antipsychotics.
How Dosing Differs by Condition
Schizophrenia
The FDA-approved range for schizophrenia is 1.5–6 mg per day. Pooled data from three large clinical trials showed that every dose in that range outperformed placebo on overall symptom scores, including negative symptoms like social withdrawal and disorganized thinking.2PubMed. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies A dose-response analysis found that the curve for negative symptoms plateaus at around 4 mg per day, while positive symptoms like hallucinations and delusions continue to improve up to about 6.5 mg per day.3npj Schizophrenia. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials In plain terms, if a prescriber is specifically targeting negative symptoms, pushing the dose above 4.5 mg may not add much benefit, while higher doses within the approved range can help more with positive symptoms.
Going above 6 mg per day is not recommended. Pooled safety data showed that patients receiving more than 6 mg daily had higher rates of movement-related side effects, weight gain, blood pressure changes, and elevations in certain blood markers. Those findings are a major reason the FDA capped the approved range where it did.4PubMed Central. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
Bipolar I Mania and Mixed Episodes
For acute manic or mixed episodes, the dose range is broader: clinical trials tested 3–12 mg per day.5PubMed. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies In practice, most patients land somewhere in the 3–6 mg range. The higher end of the scale is reserved for severe presentations where lower doses have not controlled symptoms adequately. Evidence across pooled mania trials supports efficacy throughout the 3–12 mg range, but tolerability data suggest that the 3–6 mg tier has a more favorable side effect profile than 9–12 mg.6PubMed Central. Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
Bipolar I Depression
This is where Vraylar’s dosing picture gets interesting. Unlike mania or schizophrenia, bipolar depression responds best to lower doses. A phase 3 trial found that both 1.5 mg and 3 mg per day significantly reduced depression scores compared to placebo.7PubMed. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study A second phase 3 trial, however, found that only 1.5 mg per day hit statistical significance; the 3 mg dose did not clearly separate from placebo.8PubMed Central. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study The practical takeaway: 1.5 mg per day is the best-supported dose for bipolar depression. Bumping up to 3 mg might help some people, but the evidence is less consistent, and the side effect burden starts to climb.
Major Depressive Disorder (Add-On Therapy)
Vraylar also has FDA approval as an add-on to antidepressants for major depressive disorder (MDD) in adults who have not responded well to antidepressants alone. The pivotal trial here found that 1.5 mg per day added to an existing antidepressant produced significantly greater improvement in depression scores than placebo, while 3 mg per day did not reach significance.9PubMed. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study A broader meta-analysis pooling data from both MDD and bipolar depression trials confirmed that cariprazine improved response rates in MDD, though remission rates were only clearly improved in the bipolar depression group.10PubMed. Cariprazine in the acute treatment of unipolar and bipolar depression: A systematic review and meta-analysis
A pattern emerges across depression indications: the 1.5 mg dose consistently performs well, and the 3 mg dose does not reliably add benefit while introducing more side effects. If your prescriber starts Vraylar for depression and keeps you at 1.5 mg, the data support that decision.
Why Vraylar Stays in Your System So Long
Most psychiatric medications wash out of your body in a day or two once you stop taking them. Vraylar is different. The parent drug, cariprazine, has a clinically meaningful half-life of about a day and a half. But cariprazine breaks down into two active metabolites, one of which (called DDCAR) has a half-life of about a week in practical terms. It takes roughly three weeks for DDCAR to reach steady-state blood levels, meaning the drug is still building up in your body for weeks after you start it.11PubMed Central. Population Pharmacokinetics of Cariprazine and its Major Metabolites
This has several real-world consequences. If you miss a dose or even a couple of doses, the active metabolite already circulating in your blood provides a buffer. Unlike many antipsychotics that can cause rebound symptoms within a day of a missed dose, Vraylar’s long metabolite tail means occasional missed doses are less likely to cause an abrupt loss of coverage.12Journal of Geriatric Mental Health. Cariprazine for late-life psychiatric illness: A review on therapeutic potential and challenges The flip side: if you develop a side effect, it does not go away quickly after stopping the medication. It can take weeks for the drug to fully leave your system, which means side effects may persist for an uncomfortably long time.
Akathisia and Other Side Effects at Different Doses
The most talked-about side effect of Vraylar is akathisia, a deeply uncomfortable sense of inner restlessness that makes it hard to sit still. In bipolar depression trials, about 5.5% of patients on 1.5 mg and 9.6% of patients on 3 mg experienced akathisia, compared to about 2% on placebo.13PubMed. Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression In adjunctive MDD trials, akathisia, nausea, and insomnia were the only side effects that occurred in at least 5% of patients at twice the placebo rate, and akathisia showed a clear dose-dependent pattern: higher dose, more akathisia.14PubMed Central. Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials
This dose-dependent relationship is one of the practical reasons prescribers tend to keep the dose as low as possible, especially for depression. Akathisia is not just annoying; it can be mistaken for worsening anxiety, leading to misguided dose increases that only make the problem worse. If you start feeling unusually restless after beginning or increasing Vraylar, that is worth a conversation with your prescriber before assuming your underlying condition is getting worse.
On the metabolic front, Vraylar looks relatively favorable compared to several other antipsychotics. A meta-analysis of patients with bipolar disorder and MDD found that while weight gain was statistically detectable at both the 1.5 and 3 mg doses, it was generally not clinically meaningful for most people, and there were no significant shifts in fasting glucose, triglycerides, or cholesterol compared to placebo.15PubMed. Effect of cariprazine on metabolic parameters in patients with affective disorders: A systematic review and meta-analysis
Drug Interactions That Change the Dose
Vraylar is broken down by a specific liver enzyme, and medications that interfere with this enzyme can significantly change how much active drug ends up in your bloodstream. Strong inhibitors of this enzyme can increase total cariprazine exposure by up to six-fold after extended use together. Moderate inhibitors roughly tripled it, while weak inhibitors barely moved the needle.16PubMed Central. Physiologically Based Pharmacokinetic Model-Informed Labeling for Cariprazine Drug Interactions With CYP3A Inhibitors On the other side, strong enzyme inducers can slash Vraylar’s blood levels by about 80%, potentially making it ineffective.
The practical version: if you are on a strong CYP3A4 inhibitor (certain antifungals and some HIV medications are common ones), your Vraylar dose needs to come down. If you start or stop one of these medications, your prescriber should revisit your Vraylar dose. This is not just a theoretical concern; six-fold increases in drug exposure can turn a well-tolerated dose into one that produces serious side effects.
Special Populations and Dose Adjustments
Older Adults
Safety analyses comparing different age groups from 13 to 74 years found that Vraylar’s side-effect profile was broadly similar across the age spectrum, and the same dose range appeared applicable.17PubMed Central. Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data In practice, though, older adults are more susceptible to movement-related side effects from antipsychotics in general, and the long half-life of Vraylar’s metabolites means any such side effects take weeks to resolve. The standard advice for this group is to titrate slowly and monitor for akathisia, especially in the first few weeks.18Journal of Geriatric Mental Health. Cariprazine for late-life psychiatric illness: A review on therapeutic potential and challenges
Children and Adolescents
Vraylar is not currently approved for pediatric use, but phase 1 studies have explored it in children and teens with schizophrenia or bipolar I disorder. In one dose-escalation study of 50 participants aged 10 to 17, cariprazine at doses up to 4.5 mg per day showed a pharmacokinetic profile consistent with what is seen in adults, and the drug was generally tolerated. Steady state was reached within one to two weeks for cariprazine itself and within four to five weeks for the long-acting metabolite.19PubMed. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia A separate study in children with autism spectrum disorder aged 5 to 17 used lower doses scaled by age group, going up to 3 mg per day in teens and topping out at 1.5 mg in younger children.20PubMed Central. Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study These are early-stage studies designed to figure out safe dosing, not to prove effectiveness, but they suggest that pediatric dosing will track below adult ranges for younger children.
Liver or Kidney Disease
Vraylar should not be used in people with severe liver or kidney impairment.21PubMed Central. Cariprazine for Schizophrenia and Bipolar Disorder Since the drug relies on liver enzymes for metabolism and its metabolites circulate for weeks, impaired organ function can lead to unpredictable accumulation. Mild-to-moderate impairment may not require dose adjustment, but this is an area where your prescriber needs to make a careful judgment call based on your specific lab work.
Switching To or From Vraylar
The long metabolite half-life creates a unique situation when switching antipsychotics. If you are switching away from Vraylar, the drug continues to exert effects for three to four weeks after the last dose, so there is no need for a gradual taper; you can stop it on day one and begin the new medication while the cariprazine metabolites slowly clear.22Australian Prescriber. Antipsychotic switching tool Withdrawal effects are unlikely because of this extended washout.
Switching onto Vraylar is the trickier direction. Because it takes weeks to reach full steady state, the previous antipsychotic sometimes needs to be reduced gradually over about four weeks as cariprazine builds up. Stopping the old medication too quickly can leave a gap in coverage during the transition. This overlapping-taper strategy is more relevant for Vraylar than for most other antipsychotics precisely because of its slow accumulation.
How Receptor Binding Explains the Dose Differences
Vraylar’s unusual dosing profile across indications makes more sense when you consider what it does at different doses at the receptor level. At a low dose of about 1 mg per day, brain imaging studies found that Vraylar preferentially occupied D3 dopamine receptors (about 76% occupancy) while only partially filling D2 receptors (about 45%).23PubMed Central. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO At higher doses, both receptor types approached full occupancy. D3 receptors are thought to play a larger role in mood regulation and motivation, while D2 blockade is more closely linked to control of psychotic symptoms and also to movement side effects. This helps explain why low doses work for depression (where D3 activity matters most) while schizophrenia and mania require higher doses to achieve enough D2 occupancy.
Breastfeeding and Dose Considerations
Data on Vraylar during breastfeeding is extremely limited. A small study measuring the drug in breast milk found that the combined relative infant dose for cariprazine and its metabolites was about 2.5%, which falls below the commonly cited 10% safety threshold. However, two mothers in the study reported infant drowsiness, and one case improved after the mother’s dose was lowered.24Journal of Clinical Psychopharmacology. Cariprazine in Human Milk: Cautionary Implications for Use During Lactation The long-acting metabolite adds a layer of concern here: even if the daily exposure per feeding is low, DDCAR could accumulate in an infant whose liver is not yet fully equipped to clear it. This is an area where the evidence is too thin for firm conclusions, and any decision to use Vraylar while breastfeeding needs careful, individualized risk assessment with your prescriber.
Cost and Access
Vraylar remains a brand-name medication, and its cost can be a barrier for some patients. A cost-effectiveness analysis comparing cariprazine to risperidone for schizophrenia with prominent negative symptoms found that cariprazine produced slightly more quality-adjusted life-years over two years but at a higher total cost, resulting in an incremental cost-effectiveness ratio of about 29,000 euros per additional quality-adjusted life-year gained.25Health Policy and Technology. Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia Whether that trade-off is worthwhile depends on the healthcare system and the individual patient. For people specifically struggling with negative symptoms or bipolar depression, where Vraylar has advantages that many older and cheaper antipsychotics lack, the added cost may be justified. For conditions where multiple generic alternatives work comparably, it is a harder sell financially.
Manufacturer savings programs and insurance formulary placement can dramatically affect out-of-pocket costs. If Vraylar is prescribed and cost is a concern, it is worth asking your pharmacy or prescriber about available assistance programs before assuming you cannot afford it.